Recent ECDC data show that despite progress in prevention and control efforts, the hepatitis B and hepatitis C viruses (HBV and HCV) continue to pose significant public health challenges in the European Union and European Economic Area (EU/EEA).
This is a summary of the fourth joint inter-agency report on integrated analysis of antimicrobial consumption and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals in the European Union (JIACRA IV – 2019–2021).
This report provides an integrated analysis of relationships between antimicrobial consumption in humans and food- producing animals and the occurrence of antimicrobial resistance in bacteria from humans and food- producing animals, respectively.
This course focuses on antimicrobial stewardship as an approach to address healthcare-associated infections (HAI) resulting from multi-drug resistance organisms in acute care settings.
Since the most recent ECDC rapid risk assessment in 2021, the number of EU/EEA countries reporting hypervirulent Klebsiella pneumoniae (hvKp) sequence type (ST) 23 has increased from four to ten and the number of cases reported to ECDC by the countries, increased from 12 to 143.
This document assesses the risk associated with the dissemination of carbapenemase-producing hypervirulent Klebsiella pneumoniae (hvKp) of sequence type (ST) 23 and other STs in the European Union/European Economic Area (EU/EEA).
In 2022, the first and second most reported zoonoses in humans were campylobacteriosis and salmonellosis, respectively. The number of cases of campylobacteriosis and salmonellosis remained stable in comparison with 2021.
Campylobacteriosis and salmonellosis were the most frequently reported zoonotic diseases in humans in the EU in 2022. For West Nile virus, an increase of the number of infections was observed.
A joint study of the National Public Health Organization in Greece (NPHO) and the European Centre for Disease Prevention and Control (ECDC) conducted in 15 Greek hospitals in 2022 sheds light on the rapid spread of carbapenemase-producing, highly drug-resistant Klebsiella pneumoniae sequence type (ST) 39, following its initial documentation in a European-wide genomic survey in 2019.